Abstract
Alzheimer’s Disease (AD) is a degenerative brain disease and is the most common cause of dementia. Despite being a common disease, AD is poorly understood. Current medical treatments for AD are aimed at slowing the progression of the disease. So early detection of AD is important to intervene at an early stage of the disease. In recent years, by using machine learning predictive algorithms, assisted clinic diagnosis has received great attention due to its success of machine learning advances in the domains of computer vision. In this study, we have combined brain MRI imaging features and the features of other datatypes, and adopted various models, including XGBoost, logistic regression, and k-Nearest Neighbors, to improve AD diagnosis. We evaluated the models on the benchmark dataset of Alzheimer’s Disease Neuroimaging Initiative. Experiment results show that the logistic regression model is the top performer in terms of evaluation metrics of precision, recall, and F1-score. The prediction of the models could provide valuable information for diagnosis and prognosis of patients with suspected Alzheimer’s disease. The XGBoost model achieves a comparable performance and has the potential to serve as a valuable diagnostic tool for patients with suspected AD with its self-validation by rediscovering previously known associations with AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research work was partially supported by the National Science Foundation EPSCOR DART grant, and the National Science Foundation with grant number 1452211, 1553680, and 1723529, National Institute of Health grant R01LM012601, as well as was partially supported by National Institute of Health grant from the National Institute of General Medical Sciences (P20GM103429).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* The authors JS, AK are joint first authors.
↵† Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
